NCT01793649View on ClinicalTrials.gov

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Cystic FibrosisChronic Obstructive Pulmonary Disease

Interventions

DRUG

GS-5737

A single dose of GS-5737 in 2.8% saline

Trial Locations (1)

27599

Investigational Site, Chapel Hill

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY